Stelara Prior Authorization for Oncology: Managing Co-morbid Inflammatory Conditions

Stelara's Role in Oncology Patient Care (Not as an Oncolytic)

Stelara (ustekinumab) is an IL-12/23 inhibitor indicated for the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is crucial to note that Stelara is not an oncology drug and does not treat cancer directly. However, cancer patients may have co-existing inflammatory conditions for which Stelara is medically necessary, requiring a distinct prior authorization approach focused on its approved indications within the complex context of cancer care.

Prior Authorization Documentation for Stelara in Oncology Patients

Securing prior authorization for Stelara in an oncology patient requires meticulous documentation that justifies its use for an approved inflammatory indication, while also considering the patient's overall cancer treatment plan. Payers will evaluate medical necessity against guidelines specific to Stelara's indications, alongside the broader clinical picture of the oncology patient.

Key Documentation Elements for Stelara PA in Cancer Care:

• Confirmation of an approved Stelara indication (e.g., pathology-confirmed Crohn's disease, diagnosis of moderate-to-severe psoriasis).
• Documentation of prior treatment failures or contraindications to conventional therapies for the inflammatory condition.
• Disease activity scores or objective measures (e.g., endoscopy reports, PASI scores) relevant to Stelara's indication.
• Detailed oncology treatment plan, including current and planned regimens, to assess potential drug interactions.
• Assessment of the patient's performance status (e.g., ECOG or Karnofsky score) and relevant comorbidities.
• Rationale demonstrating that Stelara use is for its approved indications and not for the underlying malignancy.

Navigating Payer Policies and Benefit Structures for Biologics

Stelara, as a specialty biologic, may fall under either the medical benefit or pharmacy benefit, impacting the PA submission channel. Medical benefit requests typically route via X12 278 transactions or payer portals, while pharmacy benefit requests route through the payer's PBM and ePA partners. For oncology patients, whose treatment regimens often involve both medical and pharmacy benefit drugs, understanding this split is critical to avoid PA delays.

Common Prior Authorization Denials for Stelara in Oncology

Denials for Stelara in oncology patients often arise from a failure to clearly delineate the medical necessity for its approved inflammatory indications, or from a misinterpretation by the payer of its role in a cancer care setting. Precision in documentation is paramount to mitigate these risks.

Frequent Denial Reasons Include:

• Insufficient documentation of an approved inflammatory indication or disease severity.
• Failure to meet payer-specific step therapy requirements for the co-morbid condition.
• Perceived 'off-label' use if the connection to the inflammatory condition is not explicitly justified.
• Documentation gaps regarding potential drug interactions with concurrent oncology therapies.
• NCD/LCD non-coverage if a payer mistakenly applies oncology-specific coverage criteria instead of inflammatory disease criteria.

Klivira's Solution for Complex Biologic PAs in Cancer Care

Klivira's prior authorization automation platform addresses the unique challenges of managing specialty biologics like Stelara for oncology patients. Our system streamlines documentation collection, applies NCCN-aware logic where relevant for the cancer context, and intelligently routes PA requests based on medical versus pharmacy benefit, ensuring that patients receive timely access to all necessary therapies without unnecessary administrative burdens.